BeiGene, Ltd. (HKG:6160)

Market Cap	226.66B
Revenue (ttm)	29.60B
Net Income (ttm)	-5.01B
Shares Out	n/a
EPS (ttm)	-47.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,659,441
Average Volume	4,123,811
Open	166.70
Previous Close	166.70
Day's Range	157.10 - 166.70
52-Week Range	75.45 - 174.80
Beta	0.64
RSI	66.35
Earnings Date	Feb 27, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10,600
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD